A pooled analysis of clinical trials testing inclisiran (Novartis) confirms the agent’s potent and durable effects on LDL cholesterol and also offers a glimpse of the drug’s potential for lowering the ...

A pooled analysis of clinical trials testing inclisiran (Novartis) that confirms the agent’s potent effects on LDL cholesterol has now been published. Yet the small interfering RNA (siRNA) molecule, ...

PHILADELPHIA--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced detailed results from ORION-9, the last of three pivotal 18-month low-density lipoprotein cholesterol (LDL-C) ...

National Institute for Health and Care Excellence (NICE) has issued new guidance which recommends inclisiran as an option for treating primary hypercholesterolaemia (heterozygous familial and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. PARIS — Inclisiran, an investigational ...

“This is a momentous occasion that further reinforces our confidence in the tremendous potential of inclisiran to fundamentally change the treatment of cardiovascular disease.” So said CEO Mark Timney ...

More patients with hypercholesterolemia at high/very high risk of cardiovascular (CV) events achieved low-density lipoprotein cholesterol (LDL-C) goals with inclisiran compared with placebo, when ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced that the results of a pre-specified analysis of secondary endpoints from the ORION-1 Phase II study were ...

Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin–kexin type 9. Previous studies suggest that inclisiran might provide sustained reductions in low-density lipoprotein (LDL) ...